Assessment of Symptoms Control, Pulmonary Function and Related Quality of Life in Asthmatic Patients Treated with Extrafine Beclomethasone Dipropionate/Formoterol Fumarate 100/6 μg pMDI: Results of a Multicenter Observational Study in Romania (ALFRESCO Study)
Ruxandra Ulmeanu,Sebastian Bloju,Oana Vittos
DOI: https://doi.org/10.2147/JAA.S358798
2022-07-08
Journal of Asthma and Allergy
Abstract:Ruxandra Ulmeanu, 1 Sebastian Bloju, 2 Oana Vittos 3 1 Postgraduate Training School of the Romanian Society of Pulmonology; Bronchoscopy Department - Institute of Pulmonology "Marius Nasta", Bucharest, Romania; 2 Medical Department, Chiesi Romania, Bucharest, Romania; 3 Clinical Research Department, Medone Research, Bucharest, Romania Correspondence: Oana Vittos, Clinical Research Department, Medone Research, 18, Alexandr Sergheevici Puskin Street, District 1, Bucharest, 011996, Romania, Tel +40 21 311 11 05, Fax +40 21 311 11 06, Email Introduction: Asthma treatment guidelines advocate the use of long-acting beta2-agonists (LABA) in addition to inhaled corticosteroids (ICS) in patients whose asthma is uncontrolled by ICS alone. This is the first study done in Romania, which collected the real-world data on the effects of Foster ® (extrafine beclomethasone dipropionate/formoterol fumarate BDP/FF in a pressurized metered-dose inhaler pMDI 100/6 μg formulation) in adult asthmatic population. Objective: We aimed to assess the asthma symptoms control, pulmonary function and quality of life parameters in a heterogeneous Romanian asthmatic adult outpatient population, treated with extrafine BDP/FF 100/6 μg pMDI. Methods: This was a prospective, multicenter, observational study involving 30 pulmonologists randomly selected from the Romanian healthcare system, which did not declare any competing interests. Recruitment period was Oct 2018 - Feb 2019, while the patients' observational period was 24 weeks. The study included poorly controlled and uncontrolled adult asthma outpatients treated with non-extrafine formulations medication, for which the treatment indication, according to Global Initiative for Asthma (GINA) 2018, was the use of an ICS-LABA combination. The study collected demographic data, smoking habits, comorbidities, data regarding asthma diagnosis, the evolution of asthma symptoms, spirometry, Asthma Control Questionnaire (ACQ-7) scoring test, current and concomitant treatment. Results: Of 302 included patients, 290 completed the study. Pulmonary function parameters assessed during the trial (forced expiratory volume in one second - FEV1 and forced vital capacity - FVC) showed a significant improvement versus baseline (p< 0.001). ACQ-7 score decreased significantly from 3.09± 0.83 (visit 1) to 1.56± 0.89 (visit 2) and to 1.09± 0.81 (visit 3) (p< 0.001). At the end of the study, 127 (43.79%) patients were well controlled (ACQ-7 score < 0.75). Conclusion: This observational study demonstrates the effectiveness and safety of extrafine fixed combination of BDP/FF (100/6 μg) pMDI in Romanian adult asthma patients uncontrolled with non-extrafine medication in a real-world setting, leading to clinically and statistically improvements in asthma control and pulmonary function. Keywords: asthma, ACQ-7, symptoms, ICS/LABA, maintenance and reliever therapy, MART Asthma is one of the most common chronic diseases worldwide in all age groups, with more than 300 million affected individuals and its prevalence keeps increasing in certain countries, 1 being at the same time a major public health problem worldwide, which might potentially negatively impact patient's quality of life. 2 The primary aim of asthma treatment is to achieve and maintain overall asthma control by reducing the severity of current symptoms and minimizing future risk regarding asthma-related mortality, exacerbations, persistent airflow limitation and side-effects. 2 Asthma treatment guidelines advocate the use of long-acting beta2-agonists (LABA) in addition to inhaled corticosteroids (ICS), either separately or as a fixed-dose formulation, in patients whose asthma is uncontrolled by ICS alone. 2,3 For ICS/formoterol fixed combination, the recommendation is the use as maintenance only or as maintenance and reliever therapy (MART). 2 The extrafine formulation of beclomethasone dipropionate/formoterol fumarate (BDP/FF) 100/6 μg in a pressurized metered-dose inhaler (pMDI) is known to produce high and homogeneous lung deposition, allowing at the same time a uniform treatment for the bronchoconstriction, as well as inflammation within the entire bronchial tree. 4–6 Also, the efficacy of BDP/FF 100/6 μg pMDI in patients with moderate to severe asthma was demonstrated in several randomized clinical trials (RCTs); 7,8 nevertheless, it should be emphasized that the effectiveness of the treatment is dependent also on other factors as the medical device used, the inhalation technique, patient's treatment adherence. Those factors are playing an important role in drug delivery and distribution along the bron -Abstract Truncated-
immunology,allergy,respiratory system